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DObjective: We sought to compare the safety and durability of bicuspid aortic valve repair versus replacement
with a bioprosthesis.
Methods:We reviewed medical records of patients aged 18 years or older undergoing bicuspid aortic valve repair
for aortic regurgitation from 1984 through 2007. We analyzed early outcomes and predictors of aortic valve re-
placement after initial repair. Patients with repair were compared with an age- and sex-matched cohort who had
replacement with a bioprosthesis. Overall survival and survival free from reoperations were compared between
groups.
Results: The mean follow-up period for 108 consecutive patients with repair was 5.1 (standard deviation, 4.1)
years. The initially repaired valve was subsequently replaced in 19 (18%) patients. No bicuspid aortic valve repair
technique or morphologic characteristic included in univariate risk factor analysis was associated with increased
probability of replacement after initial repair. The 5- and 10-year survival rates after repair were 96% and 87%,
respectively. Freedom from valve replacement was 96%, 89%, and 49% at 1, 5, and 10 years after repair, respec-
tively. A separate analysis of 81 matched patients with repair or receipt of an aortic valve bioprosthesis showed no
significant difference in 10-year survival (72% vs 79%, P ¼ .13) or freedom from reoperation between groups
(90% vs 98% and 72% vs 64% in 5 and 10 years, respectively; P< .12).
Conclusions: Bicuspid aortic valve repair is a viable alternative to replacement with a bioprosthesis because
durability and safety are similar between both surgical management methods for aortic regurgitation. After initial
repair, approximately half of the patients require aortic valve replacement within 10 years. (J Thorac Cardiovasc
Surg 2010;139:1395-401)Earn CME credits at
http://cme.ctsnetjournals.org
Bicuspid aortic valve (BAV) is a congenital anomaly with an
estimated incidence in the general population of 2.5% as re-
ported in epidemiologic reports1 and 0.9% as reported in
necropsy studies.2 It is associated with aortic valve (AV)
dysfunction3: up to 85% of patients with BAV have aortic
stenosis after the fifth decade of life. Isolated aortic regurgi-
tation (AR) is less common, affects approximately one fifth
of patients with BAV, and usually manifests earlier in life
than aortic stenosis.4 Because the population of patients
with BAV is relatively young, the optimal surgical treatment
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The Journal of Thoracic and Carand longevity. BAV repair seems to be a viable alternative to
replacement techniques because it avoids complications
related to artificial valves and long-term anticoagulation.
During the past 2 decades, AV repair has gained more accep-
tance among surgeons; nevertheless, the technique is still in
evolution. We present our clinic’s recent experience in BAV
repair for AR, with emphasis on risks of reoperation and late
cardiac death.MATERIALS AND METHODS
After receiving study approval by the Mayo Clinic Institutional Review
Board, we searched our clinic database for patients aged 18 years or older
who underwent BAV repair for AR with or without concomitant supracoro-
nary tube graft replacement of the ascending aorta for aortic dilatation from
1984 through 2007. We excluded patients with valve-sparing aortic root re-
placements (David and Yacoub operations), aortic stenosis, aortic dissec-
tions, prior balloon valvuloplasty, or surgical valvulotomy, and we
excluded patients with iatrogenic AR acquired intraoperatively after graft
replacement of the aorta or trauma to the AV.
We reviewed medical records of study patients to obtain demographic
characteristics and results of echocardiographic examinations, and we re-
viewed surgical records for valve morphologic features and techniques of
repair. Late follow-up was obtained from clinical records when available,
from written correspondence with patients’ physicians, or from question-
naires mailed directly to the patient and up to the latest date available.
Because some degree of annular dilatation is common in patients with
regurgitant BAVs, we combined cusp repair with commissural plication
to decrease the diameter of the aortic annulus.5 If the mid–ascending aortadiovascular Surgery c Volume 139, Number 6 1395
Abbreviations and Acronyms
AR ¼ aortic regurgitation
AV ¼ aortic valve
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
SD ¼ standard deviation
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Dhad a dilatation of greater than 45 mm, it was replaced with a supracoronary
tube graft.
Operations were performed with normothermic cardiopulmonary by-
pass, and hypothermic antegrade blood cardioplegia was used for myocar-
dial protection. The standard technique for surgical treatment of AR in
a patient with BAV has undergone evolution over time. Before 2000,
most valves were repaired with triangular resection and suture repair of
the median raphe.6 After 2000 and in patients with pliable cusps, prolapse
was most likely corrected with plication of the median raphe without resec-
tion. Intraoperative transesophageal echocardiographic analysis was used
for all study patients.
Univariate analysis was performed to identify risk factors significant for
BAV replacement after initial repair. The durability of BAV repair was eval-
uated by estimating the freedom from aortic valve replacement (AVR).
Safety of the procedure was judged with the incidence of early postoperative
complications and survival. To evaluate the influence of change in operative
techniques depending on the era of operation, we divided study patients into
2 subgroups (ie, those who underwent operations before 2000 and those
who underwent operations in 2000 or later) and compared results of analysis
of freedom from AVR between the 2 subgroups. Furthermore, we
performed the same analysis, excluding patients who had AVR but whose
primary indication for reoperation was not BAV repair failure.
To assess the feasibility of BAV repair compared with other conven-
tional techniques of AR management, we matched our study cohort with
patients who underwent AVR with a bioprosthesis; patients were matched
by year of operation (5 years), age, and sex. Survival and freedom from
reoperation were compared between the 2 groups.
Descriptive statistics for categorical variables are reported as frequencies
and percentages; continuous variables are reported as means (standard
deviations [SDs]) or medians (ranges), as appropriate. Categorical variables
were compared with the c2 test. Continuous variables were compared with
the 2-sample t test or Wilcoxon rank sum test, as appropriate. The Kaplan–
Meier method was used to draw survival curves and calculate 5- and 10-year
survival statistics and freedom fromAVR. Cox proportional hazards regres-
sion models were used to find the univariate predictors of time of AVR.
RESULTS
The study group contained 108 consecutive patients who
met the inclusion criteria and had given consent to partici-
pate in research. Baseline characteristics of patients under-
going BAV repair are listed in Table 1. The mean age was
41 years, and most patients were men. No patient had acute
endocarditis; 9 (8%) patients had healed lesions and a his-
tory of treated endocarditis. The primary indication for the
operation was moderately severe or severe AR in 90
(83%) patients, and severe mitral regurgitation was associ-
ated with at least moderate AR in 9 (8%) patients. Another
9 patients were sent to the surgical department because of an
ascending aortic aneurysm and had concomitant repair of
significant AR.1396 The Journal of Thoracic and Cardiovascular SurOperative Techniques
Isolated BAV repair was performed in 61 (56%) patients.
AV repair was combined with graft replacement in
15 patients and with reduction aortoplasty in 8 patients for
dilatation of the ascending aorta (minimum, 49 mm); 11 pa-
tients had concomitant mitral valve repair. Other concomi-
tant procedures are listed in Table 1.
Surgical inspection identified a number of mechanisms
of BAV regurgitation. The most common finding was scar-
ring and retraction of the rudimentary raphe of a conjoint
cusp. Other mechanisms included prolapse of both aortic
cusps or of a conjoint cusp. In general, the cusps were
thin and pliable, and in 83 (77%) patients the cusps had
no calcification.
The most common technique for BAV repair was com-
missural plication combined with triangular resection of
the retracted rudimentary raphe. Overall, 101 patients had
commissural plication. However, the operative methods
changed over time. From 1984 through 1999, the retracted
median raphe was excised in 24 patients and plicated in 1 pa-
tient; from 2000 through 2007, the raphe was excised in 39
patients and plicated in 19 patients.
After initial termination, cardiopulmonary bypass was re-
sumed in 8 (7%) patients: for residual AR noted with intra-
operative transesophageal echocardiographic analysis in 5
patients; for mitral valve repair, tricuspid valve repair, or
both in 2 patients; and for closure of an iatrogenic ventricular
septal defect acquired during decalcification of the interven-
tricular septum in 1 patient. In 2 patients a brief period of cir-
culatory arrest (12 and 15 minutes, respectively) was used to
facilitate distal anastomoses of graft repair of ascending aor-
tic aneurysms.
Intraoperative transesophageal echocardiographic analy-
sis was performed in 105 (97%) patients; 3 patients without
transesophageal echocardiographic analysis underwent op-
erations in 1984 (2 patients) and 1986 (1 patient). None of
the patients left the operating room with greater than mild re-
sidual AR, and the mean transvalvular gradient was 16 mm
Hg (SD, 9 mm Hg).
Echocardiographic Characteristics
All patients with BAV underwent preoperative transtho-
racic echocardiographic analysis. The mean grade of AR
in study patients was 3.2 (SD, 1.0) on a scale of 1 to 4.
For most patients, left ventricular systolic function was nor-
mal; the mean of the left ventricular ejection fraction was
59% (SD, 6%). Aortopathy was common, and the mean di-
ameter of the proximal ascending aorta was 41 mm (SD, 5
mm) in the study compared with 26 mm (SD, 3 mm) re-
ported as a reference range by Triulzi and colleagues.7
Results of postoperative follow-up echocardiographic
analyses at least 1 year after BAV repair were available in
46 (43%) patients who were free from AVR (Table 2).
Statistically significant decreases in the left ventriculargery c June 2010
TABLE 1. Baseline characteristics of patients undergoing bicuspid
aortic valve repair
Characteristics
Value*
(n ¼ 108)
Age, mean (SD), y 41 (13)
Male sex 98 (91)
Body mass index, mean (SD), kg/m2 27.6 (5.0)
Cardiac pathologic features
Aortic aneurysm 23 (21)
Prior infectious endocarditis 9 (8)
Coronary artery disease 10 (9)
Prior cardiac operation
Coarctation repair 10 (9)
New York Heart Association class
I 50 (46)
II 37 (34)
III 19 (18)
IV 2 (2)
Cardiopulmonary bypass time, mean (SD), min 51 (26)
Crossclamping time, mean (SD), min 38 (17)
Concomitant procedures
Graft replacement of ascending aorta 15 (14)
Reduction aortoplasty 8 (7)
Mitral valve repair 11 (10)
Tricuspid valve repair 2 (2)
Coronary artery bypass grafting 8 (7)
Arterial septal defect/patent foramen ovale closure 6 (6)
Ventricular septal defect 5 (5)
Maze procedure 2 (2)
Coarctation repair 1 (1)
Morphologic featuresy
Scarring of rudimentary raphe 49 (45)
Calcification of rudimentary raphe 16 (15)
Prolapse of both cusps 36 (33)
Prolapse of a single cusp
Conjoint 32 (30)
Nonconjoint 0
Calcification of cusps 9 (8)
Perforation of cusps 5 (5)
Operative techniques
Commissural plication 101 (94)
Triangular excision of raphe 63 (58)
Plication of raphe 20 (19)
Plication of free edge of conjoined cusp 14 (13)
Plication of free edge of nonconjoined cusp 18 (17)
Patch repair of cusp perforation 9 (8)
Decalcification 4 (4)
Cusp shaving 3 (3)
Partial noncoronary cusp resection with plication 3 (3)
SD, Standard deviation. *Values are expressed as numbers (percentages) of patients
unless specified otherwise. yAs described by the operating surgeon.
TABLE 2. Echocardiographic changes for patients with echocardio-
graphic follow-up of 1 year or more after BAV repair
Patients (n ¼ 46)*
Characteristic
Before
BAV repair,
mean (SD)
After
BAV repair,
mean (SD)
P
value
LVEF,% 59 (6) 61 (7) .19
LV end-diastolic dimension, mm 61 (8) 54 (6) <.001
LV end-systolic dimension, mm 41 (6) 36 (7) <.001
LV mass, g 286 (70) 232 (63) <.001
LA volume index, mL/m2 31 (14) 30 (9) .22
Aortic dimensions, mm
Annulus 29 (4) 28 (4) .69
Valsalva sinuses 42 (6) 41 (6) .82
Sinotubular junction 35 (5) 34 (7) .35
Proximal ascending aorta 42 (6) 38 (7) .36
Mid–ascending aorta 41 (8) 37 (7) .37
Aortic arch 31 (6) 30 (6) .79
Mean AV pressure gradient, mm Hg 10 (4) 17 (10) <.001
AV orifice (TVI), cm2 3.8 (1.5) 2.4 (1.0) <.001
Regurgitation grade (scale, 1–4)
Aortic valve 3.1 (1.0) 1.2 (0.8) <.001
Mitral valve 1.0 (0.8) 1.0 (0.5) .95
Tricuspid valve 0.8 (0.4) 1.0 (0.2) .07
Pulmonary valve 0.6 (0.5) 0.9 (0.4) .28
RV systolic pressure, mm Hg 34 (12) 31 (7) .62
BAV, Bicuspid aortic valve; SD, standard deviation; LVEF, left ventricular ejection
fraction; LV, left ventricular; LA, left atrium; AV, aortic valve; TVI, time velocity
integral; RV, right ventricular. *Patients free from AVR; mean echocardiographic
follow-up was 4.6 years (SD, 3.5 years; maximum, 12.7 years).
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Dsystolic and diastolic dimensions and the left ventricular
mass were observed at a mean of 4.6 years (SD, 3.5 years)
after BAV repair. A decrease in AV orifice and augmenta-
tion of gradient across the AV were consequences of AV re-
pair technique.The Journal of Thoracic and CarOutcomes, Safety, and Durability of BAV Repair
Among the 108 patients undergoing BAV repair, the
mean follow-up period was 5.1 years (SD, 4.1 years; me-
dian, 4.1 years; range, 5 days to 22.9 years). In 2 patients
no follow-up information was available beyond the initial
hospitalization. Follow-up beyond the first postoperative
year was available for 95 (88%) patients, and 15 (14%)
patients had follow-up beyond 10 years postoperatively.
No early deaths occurred, and 7 (6%) patients died late.
Cause of death was unknown in 4 patients, death was cardiac
related in 2 patients, and 1 patient died suddenly. The 1-, 5-,
and 10-year survival rates were 99%, 96%, and 87%,
respectively, which are similar to those of an age- and sex-
matched general population (Figure 1, A).
Overall, 19 patients had subsequent AVR, and cumulative
risk of reoperation for AVR is shown in Figure 1, B. Two
AVRs were performed during initial hospitalization because
of severe AR identified 4 and 6 days, respectively, after ini-
tial BAV repair. One patient underwent BAV rerepair during
the same hospitalization; his valve was subsequently re-
placed 2 years postoperatively. Failure of the repair was
the primary indication for reoperation in 14 of the 19 pa-
tients. The repair failure led to severe AR in 9 patients, aortic
stenosis in 2 patients, and mixed aortic stenosis and AR in 1diovascular Surgery c Volume 139, Number 6 1397
FIGURE 1. Survival and risk of aortic valve replacement (AVR) after bicuspid aortic valve (BAV) repair. A, Survival of patients with BAV repair compared
with a Minnesota population of white patients of the same age and sex. B, Risk of AVR for patients with BAV repair. C, Risk of AVR for patients with BAV
repair stratified by year of operation. D, Risk of AVR for patients with BAV repair stratified by year of operation after exclusion of patients who underwent
reoperation for indications not related to BAV repair failure.
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known. For 5 patients, late AVR was performed during a re-
operation for aortic aneurysm (n ¼ 1), aortic dissection
(n ¼ 1), severe angina (n ¼ 1), severe mitral regurgitation
(n ¼ 1), and persistent hemolysis (n ¼ 1), likely because
of red cell trauma from an annuloplasty ring used during
prior concomitant mitral valve repair.
At reoperation for AVR, 17 patients received mechanical
prostheses, and 2 patients received bioprostheses. AVR was
combined with mitral valve replacement in 2 patients and
with coronary artery bypass grafting in 1 patient.
To evaluate the possible effect of a surgeon’s learning
curve for the procedure, we stratified patients according to
the era of operation. We found that there was a tendency to-
ward a lower risk of reoperation for AVR in patients who un-
derwent repair in 2000 or later (P ¼ .06; Figure 1, C). To
eliminate the confounding effect of late AVR during surgical
intervention for another cardiac problem, we performed
a similar analysis that included only the 14 patients who
had late AVR caused by failure of the initial repair. The anal-
ysis showed that the tendency toward improved outcome in
recent years persisted (Figure 1, D).
Outcomes, Safety, and Durability of BAV Repair
Versus AVR With a Bioprosthesis
To place the outcomes of BAV repair in perspective, we
matched these patients for age, sex, and year of operation
to control patients who had AVR with bioprostheses. We1398 The Journal of Thoracic and Cardiovascular Surwere able to identify 81 matched pairs from our database.
Most (68%) of the group had AVR with Carpentier–Ed-
wards pericardial bioprostheses. The mean age was 44 years
(SD, 13 years) for patients with BAV repair and 45 years
(SD, 13 years) for patients with AV bioprostheses
(P ¼ .33). Durations of cardiopulmonary bypass and cross-
clamping were longer in patients with AVR than in those
with BAV repair (89 minutes [SD, 44 minutes] vs 53 min-
utes [SD, 27 minutes] and 66 minutes [SD, 34 minutes] vs
39 minutes [SD, 18 minutes], respectively; P< .001).
The length of available follow-up was similar among pa-
tients with BAV repairs and patients with AVR (4.2 years
[SD, 3.2 years] vs 4.2 years [SD, 3.5 years]). Overall sur-
vival was similar for patients undergoing valve repair and
those undergoing valve replacement (Figure 2, A). Risk of
reoperation was also similar between the 2 groups
(P ¼ .12; Figure 2, B). Among matched patients with
BAV repairs, 4 underwent reoperation because of causes un-
related to failure of BAV repair. After excluding these pa-
tients (and their matching cohort with bioprostheses), we
again compared the risk of reoperation between the 2 groups
(n ¼ 77) and found no statistical difference in freedom from
reoperation (P ¼ .66; Figure 2, C).
Early postoperative complications were more frequent
among patients with AVR. Overall, 37 (46%) patients
with aortic bioprostheses had complicated postoperative re-
covery; in the BAV repair group 24 (30%) patients had
some complication after surgical intervention (P ¼ .04).gery c June 2010
FIGURE 2. Survival and risk of reoperation in matched groups after bicuspid aortic valve (BAV) repair and aortic valve replacement (AVR) with a biopros-
thesis. A, Survival of patients after BAV repair matched to patients who underwent AVRwith a bioprosthesis. B, Risk of reoperation in matched patients who
underwent BAV repair or AVRwith a bioprosthesis. C, Risk of reoperation in matched patients who underwent BAV repair or AVRwith a bioprosthesis after
exclusion of patients and their matched pairs who underwent reoperation for indications not related to BAV repair failure.
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ment of prolonged mechanical ventilation in 6 (7%) patients
with AVR; no patient with BAV repair received mechanical
ventilation for more than 24 hours (P¼ .03). No statistically
significant difference was found in the incidence of any
other early postoperative complications, such as sternal
wound infection (P ¼ .99), renal failure (P ¼ .99), onset
of atrial fibrillation (P ¼ .13), pneumonia (P ¼ .12), sepsis
(P ¼ .50), or re-exploration for bleeding (P ¼ .99). During
late follow-up, endocarditis was reported in 4 patients who
had AVR, and stroke occurred in 3 patients; no episode of
endocarditis or stroke occurred in patients who had BAV
repair.
Risk Factors of BAV Repair Failure
Several candidate variables were entered into the univar-
iate analysis to discriminate potential risk factors related to
time of AVR: age at original BAV repair; sex; body mass in-
dex; year of operation; era of operation (before 2000 or after
2000); left ventricular function; concomitant cardiac patho-
logic factors (eg, coarctation); AV morphologic characteris-
tics as described by the operating surgeon, including
calcification; AV repair techniques; concomitant proce-
dures; and the mean AV gradient at recent follow-up trans-
thoracic echocardiographic analysis. None of these variables
were statistically significant in predicting the risk of AVR af-
ter BAV repair as it related to time of replacement.The Journal of Thoracic and CarDISCUSSION
AV repair has several potential advantages over AVR for
younger patients with AR caused by BAV. Although valve
repair often includes commissural plication sutures, which
can narrow the annulus, preservation of the dynamics of
the native valve annulus and tissue might have hemody-
namic benefits over a rigid prosthetic valve stent. Also, risks
of thromboembolic events, anticoagulation-related compli-
cations, and endocarditis appear to be reduced after valve re-
pair8 compared with after replacement. However, as outlined
in the 2006 American College of Cardiology/American
Heart Association Guidelines for the Management of Pa-
tients With Valvular Heart Disease,9 AV repair involves
a ‘‘lack of uniform applicability [and] lack of widespread ex-
perience with surgical techniques.’’ Furthermore, there are
no clear indications on when repair should be attempted,
and data showing its safety and durability are limited.
Most publications in the medical literature report either a rel-
atively short follow-up period (2–4 years)10-12 or a small
number of patients with a longer follow-up period.13,14
Also, assessment of results of AV repair is confounded
because most reports describe mixed groups of patients, in-
cluding those with tricuspid and bicuspid valve repairs, as
well as valve repair performed during procedures for aortic
root reconstruction. In a study of 54 patients, Rao and asso-
ciates13 reported survival rates of 98% and 74%, respec-
tively, at 5 and 10 years after repair of AR for patientsdiovascular Surgery c Volume 139, Number 6 1399
TABLE 3. Freedom from reoperation for patients undergoing bicuspid aortic valve repair
Patients free from
reoperation,%*
Study report Follow-up, mean (SD), y Years of study No. of patients Age, mean (SD), y 1 y 5 y 7–8 y 10 y
Alsoufi and coworkers16 3.5 (2.7) 1993–2005 71 42 (13) 97 90 82 NA
Casselman and coworkers17 5.1 (2.4) 1988–1997 94 38 (10) 95 87 84 NA
Davierwala and coworkers11 2.6 (2.1) 1993–2002 44 39 (12) 95 91 NA NA
Fraser and coworkers10 2.0 (1.3) 1988–1993 72 39 (11) 94 NA NA NA
Kin and coworkers18 3.3 (1.9) 1993–2000 19 42 (17) 87 76 NA NA
Present study 5.1 (4.1) 1984–2007 108 41 (13) 96 89 75 49
SD, Standard deviation; NA, not applicable. *According to mean years of follow-up after bicuspid aortic valve repair.
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BAV. de Kerchove and coworkers8 reported a 99% 4-year
survival rate for patients with AV repair, of whom 53%
had BAV. In an earlier study from our institution in a mixed
group of patients undergoing AV repairs, of whom 34% had
BAV, freedom from cardiac death was 96% at 5 years.7
In contrast to these earlier reports, the present investiga-
tion focused on outcomes of a homogenous group of patients
with regurgitation of a BAV. After valve repair, patient sur-
vival rates at 1, 5, and 10 years postoperatively were 99%,
96%, and 87%, respectively, which are similar to those of
the general US population. We also observed no significant
difference in the survival of patients undergoing BAV repair
compared with that seen in matched patients undergoing
AVR with a bioprosthesis (P ¼ .13), again supporting the
safety of this strategy for patients with severe regurgitation
caused by BAV.
The primary concerns of AV repair are durability and risk
of surgical reintervention. In a series of 173 patients under-
going BAV repair, Schafers and associates15 reported
a 5-year rate of 94% for freedom from any reoperation after
isolated BAV repair, 97% after repair and aortic root recon-
struction, and 53% after repair combined with replacement
of the ascending aorta; the rate of freedom from AVR was
98%, 99%, and 80%, respectively. Table 310,11,16-18
summarizes results of other reports that provide detailed
information on freedom of reoperation after BAV repair.
Few of these studies had a follow-up beyond 5 years.
The American College of Cardiology/American Heart As-
sociation guidelines report that by 10 years of follow-up, the
overall rate of AVR after prior AV repair is approximately
15%.9 The overall risk of reoperation in our study was
18%, but this percentage includes AVR performed during re-
operation for other indications. The overall risk of AVR for
failure of initial repair was 16%. Indeed, the cumulative risk
of reoperation for failure of initial repair was seen to increase
after 5 years, as did the risk of reoperation in our matched pa-
tientswith bioprostheses. It appears that late results of repair of
BAV have improved in the most recent decade (Figure 2, C),
likely because of improved patient selection.
Although our statistical analysis did not identify preoper-
ative hemodynamic and morphologic features that predicted1400 The Journal of Thoracic and Cardiovascular Sura need for late reoperation, experience has shown thatmarked
thickening of cusps and calcification are unfavorable charac-
teristics. We agree with the systematic approach suggested
by Pettersson and colleagues5 based on the echocardio-
graphic evaluation. In their study conjoint cusp tissue restric-
tion and deficiency, combined with cusp thickening and
cusp calcification, were unfavorable features for reparability.
We believe that these characteristics also influence late dura-
bility when such valves are repaired. Important, too, are the
criteria for successful repair, which include a grade of AR
of 1 or less and a mean AV gradient of less than 15 mm Hg
or a peak AV gradient of less than 30 mm Hg.5
Nevertheless, the cause of deterioration of BAV repair
continues to be unclear. Several studies have investigated
risk factors for failure of BAV repair.8,17,19 Casselman and
coworkers17 described left ventricular dysfunction as a pre-
dictor of immediate, persistent AR of more than þ1 after
BAV repair, but they did not identify risk factors for late re-
gurgitation. Nash and colleagues19 reported echocardio-
graphic parameters associated with increased likelihood of
successful BAV repair, and these parameters included an ec-
centric jet of AR, absence of cuspal or commissural thicken-
ing, and lack of cusp calcification. Multivariate analysis by
de Kerchove and coworkers8 suggested that methods of re-
pair of the prolapsed cusp and increased left ventricular
end-diastolic diameter were predictors of BAV repair fail-
ure. In our study none of the variables that potentially could
increase the risk of AVR after BAV repair turned out to be
statistically significant. It is possible that some other factors
that were not tested but were associated with repair failure or
with the numbers of patients and events (replacements), as
well as the duration of follow-up, were not sufficient to iden-
tify risk factors.
Debates are ongoing over the most reliable technique of
AV repair. The change of surgical technique from triangular
resection to tissue-sparing plication of the midportion of the
conjoint cusp is expected to improve repair durability. How-
ever, in the series reported by Aicher and associates,14 trian-
gular resection of a portion of the prolapsing cusp did not
compromise midterm durability of repair. Our current pref-
erence for plication rather than cusp resection evolved
with increasing experience. We initially followed thegery c June 2010
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volved excision of the raphe of the prolapsing cusp, and this
method is still useful when there is marked thickening of this
area. However, when the conjoint cusp is very pliable and
thickness is near normal, plication to shorten the free edge
is done easily and avoids risk of sutures pulling through
the thinner areas of the midcusp. Although not statistically
significant, the rate of reoperation after BAV repair for pa-
tients who underwent operations after 2000 was lower
than for patients undergoing operations in the previous de-
cade. This lower rate likely reflects improved patient selec-
tion, as well as use of the plication method.
An important finding in the present study was the compa-
rability of risk of reoperation for patients undergoing BAV
repair versus AVR with a bioprosthesis. As shown in
Figure 2, B and C, the cumulative risk of reoperation for pa-
tients with a bioprosthesis appears to increase sharply after 8
years, although our follow-up beyond this time is limited.
Goland and associates21 reported that the risk of reoperation
10 years after AVR with a bioprosthesis reached 30% to
50% depending on the decade when the initial operation
was performed. In addition to the relatively high rate of re-
intervention, patients undergoing AVR with a bioprosthesis
are still at risk for prosthetic valve–related complications,
particularly prosthetic valve endocarditis and thromboembo-
lism, and the risks of these complications were notably low
(ie, no events) among patients undergoing valve repair.Study Limitations
The mean age of the study patients was 41 years (SD, 13
years), and our reported results do not assess the safety and
durability of BAV repair in a younger population. All pa-
tients in the study had preserved left ventricular ejection
fraction (45%), and thus no conclusion can be made about
the feasibility of BAV repair in patients with impaired myo-
cardial performance. Also, the follow-up period is relatively
short; with additional time, repaired valves might have cal-
cification and stenosis. As previously reported, we matched
control patients with bioprostheses for only 81 of the 108 pa-
tients in the overall study. Nevertheless, our data provide
a longer follow-up period on repaired BAV than prior re-
ports. Finally, the end point of our statistical analysis was
reoperation but not the grade of AR, and thus the incidence
of severe AR (eg, repair failure) might be underestimated.CONCLUSION
BAV repair is a safe and durable technique for AR man-
agement. It is a viable alternative to AVR with a bioprosthe-
sis because a comparison of these 2 therapeutic approaches
shows no advantage in survival and durability.The Journal of Thoracic and CarReferences
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